EBRT works better with ADT for intermediate- and high-risk prostate cancer

The EORTC trial 22991 was designed and implemented to compare external beam radiation therapy (EBRT) + short-term androgen deprivation therapy (ADT) to EBRT alone as first-line therapy in patients with intermediate- and high-risk prostate cancer. … READ MORE …

Brachytherapy boost may lower mortality rate in high-risk patients

The ASCENDE-RT randomized clinical trial demonstrated that the combination of external beam radiation therapy with a brachytherapy boost (EBRT + BT) significantly reduced biochemical progression-free survival. … READ MORE …

Early data from the ASCENDE-RT trial misleadingly presented

News reports (and apparently a media release) have been suggesting that ‘A prostate cancer treatment using permanently implanted radioactive “seeds” doubles rates of 5-year tumor-free survival compared with conventional high-dose radiotherapy.’ Unfortunately, these reports are somewhat — or perhaps very — misleading. … READ MORE …

EBRT + LDRBT boost provides superior cancer control compared to EBRT alone

Numerous retrospective analyses have suggested that the combination of external beam radiation therapy (EBRT) with a low-dose-rate brachytherapy (LDRBT) boost is highly effective in controlling prostate cancer in unfavorable-risk patients. … READ MORE …

10-year survival data from the RT01 trial of differing doses of 3D-CRT

According to a paper just published in Lancet Oncology today, the 10-year follow-up results of the RT01 trial carried out under the auspices of the British Medical Research Council have shown an overall survival of 71 percent in both arms of this trial of two types of external beam radiation therapy. … READ MORE …

5-year survival of high-risk patients after EBRT + brachytherapy

Long-term data on survival of high-risk patients after treatment with a combination of external beam radiation therapy (EBRT) and brachytherapy (radioactive seed implantation), with or without neoadjuvant and adjuvant androgen deprivation therapy (ADT), are not well established as yet. … READ MORE …

Radiation therapy for localized prostate cancer in men with diabetes mellitus

A new paper recently published on line in Urology (“the Gold Journal”) suggests that men with diabetes who are treated with curative intent for localized prostate cancer using external beam radiation therapy may experience higher than normal risk for late genitourinary complications and adverse effects. … READ MORE …